AR and neoplasm: Three of four patients classed as partial responders, for whom pre-treatment tissue biopsy was available for androgen receptor splice variant 7 (AR-V7) immunohistochemistry (IHC) including the patient who received only abiraterone previously, had tumour expressing AR-V7 protein.